Targeting activated matriptase-positive tumor cells should eliminate those cells that have the propensity to initiate tumor progression driven by HGF/MET and PAR-2 mediated pathways as well as those with potential to acquire invasive and metastatic phenotypes that are driven by an acidic microenvironment. Here, MET is linked to neoplasm.